Cheng Shin Rubber Industry Co (正新橡膠), the world’s ninth-largest tire maker, is considering building its seventh plant in China to deepen its presence there.
With six factories in southern and central China, Cheng Shin’s plan to construct a new plant in northern China would help it satisfy growing demand, vice president Wu Hsuan-miao (吳軒妙) said yesterday.
Wu made the remarks after the company held its annual general meeting in Yuanlin (員林), Changhua County, where shareholders agreed to the company’s proposal to distribute a cash dividend of NT$1.5 and a stock dividend of 15 percent, based on last year’s earnings of NT$8.54 billion, or NT$5.64 per share.
“We will come up with a concrete plan on the construction of a new plant early next year, when the global demand for tires is set to stabilize,” Wu said by telephone.
Cheng Shin needs to expand its production capacity to meet demand, as the company’s existing factories are likely to reach full capacity by the end of this year, from about 90 percent capacity at the moment, Wu said.
Cheng Shin, known for its brands CST, Maxxis, Sakura and Presa, also expects its revenue to rise steadily this year from last year on the back of rising car sales in emerging markets and lower raw material costs.
“Demand in China and other emerging markets, such as India and Indonesia, is growing faster than in developed countries,” the company said in a report distributed to shareholders.
Barclays Capital analyst Sidney Yeh (葉昌明) said Cheng Shin is better positioned than its peers in terms of geographic exposure to the European and US markets, where tire demand is weakening.
“Cheng Shin derived 9 percent of its sales from European and North American markets last year,” Yeh said in a note on Tuesday last week. “The exposure is much smaller than [that of] global peers, such as Michelin, Bridgestone, Goodyear and Hankook.”
The company’s combined sales to China and other emerging markets accounted for about 70 percent to 80 percent of its total revenue of NT$12.6 billion (US$420.83 million) in the January-to-March quarter, Wu said.
With the completion of three new factories in China and one in Taiwan in the past year, the company’s total sales of tires are expected to reach 39.2 million units this year, a more than 300 percent increase from 11.26 million units the previous year, the company said. It did not yesterday give revenue and earnings forecasts for this year.
Fubon Securities Investment Services Co (富邦投顧) analyst Will Hsieh (謝文凱) said in a note on May 15 that Cheng Shin could grow its revenue by 10 percent to NT$143.26 billion this year from last year, with net profit increasing 16.9 percent year-on-year to NT$19.45 billion, or NT$6.9 per share.
Cheng Shin shares rose 0.86 percent to NT$93.8 yesterday.
Cash-strapped developer China Evergrande Group (恆大集團) has begun repaying investors in its wealth management products with real estate, said Hengda Real Estate Group Co Ltd (恆大地產), its main unit. Evergrande, with more than US$300 billion in liabilities, is in the throes of a liquidity crisis that has left it racing to raise funds to pay its many lenders and suppliers. It has a bond interest payment of US$83.5 million due on Thursday. The company said on WeChat on Saturday that investors interested in redeeming wealth management products for physical assets should contact their investment consultants or visit local offices. Financial news outlet Caixin on
WORK SUSPENDED: A Taiwanese maker of golf club heads said that it expects the situation to normalize next quarter, thanks to rising vaccination rates in Vietnam Several Taiwanese manufacturers in Vietnam have been struggling with production problems over the past few weeks, as the country’s south remains under a COVID-19 lockdown. Pou Chen Corp (寶成工業), an original design manufacturer for international footwear brands, said that production at its factory in Ho Chi Minh City has ground to a halt, so it expects a significant drop in revenue at that factory from July to last month. If the COVID-19 outbreak in southern Vietnam subsides in the fourth quarter of this year and employees are allowed to return to work, they might be able to put in some overtime,
Medigen Vaccine Biologics Corp’s (高端疫苗) board of directors yesterday approved a proposal to conduct a phase 3 clinical trial of its COVID-19 vaccine in Europe, it said yesterday. The final stage of human tests, if approved by the European Medicines Agency (EMA), would mark a big milestone in the COVID-19 vaccine development of Medigen, which has so far completed phase 1 and 2 clinical trials in Taiwan and is conducting a small phase 3 clinical trial in Paraguay. Medigen in July consulted the EMA about conducting clinicial trials of its vaccine and it received a “positive response” from the agency, the company
‘CORE VALUES’: The contract chipmaker did not specify why the employees were dismissed, but media reports said they had leaked information about customer orders Taiwan Semiconductor Manufacturing Co (TSMC, 台積電) has fired seven of its employees for violating the company’s “core values,” the world’s largest contract chipmaker said yesterday. While the company did not disclose exactly why it fired the seven employees, local media reports earlier in the day said that the employees had leaked confidential information about customer orders. In a statement, the company said that it fired the seven at once, adding that it released an internal notice last week to inform the entire company of the move ahead of the four-day Mid-Autumn Festival holilday, which ended on Tuesday. TSMC said it fired the seven